Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2017 Summary According to the recently published report 'Protein Phosphatase 2A - Pipeline Review, H1 2017'; Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer. The report 'Protein Phosphatase 2A - Pipeline Review, H1 2017' outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Ophthalmology and Respiratory which include indications Alzheimer's Disease, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Allergic Conjunctivitis, Asthma, Brain Ischemia, Breast Cancer, Breast Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Endometrial Cancer, Idiopathic Pulmonary Fibrosis, Lung Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myocardial Ischemia, Neuroblastoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Pancreatic Cancer, Parkinson's Disease, Prostate Cancer, Renal Cell Carcinoma, Septic Shock, Small-Cell Lung Cancer, Solid Tumor, T-Cell Leukemia, Ulcerative Colitis, Uveal Melanoma and Uveitis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects - The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Overview Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development Ampio Pharmaceuticals Inc Bristol-Myers Squibb Company Cyano Biotech GmbH Lixte Biotechnology Holdings Inc PEP-Therapy SAS Re-Pharm Ltd Signum Biosciences Inc Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles Drugs to Activate PP2A for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress DT-1154 - Drug Profile Product Description Mechanism Of Action R&D Progress LB-100 - Drug Profile Product Description Mechanism Of Action R&D Progress NCE-001 - Drug Profile Product Description Mechanism Of Action R&D Progress PEP-010 - Drug Profile Product Description Mechanism Of Action R&D Progress RP-0217 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate PP2A for Parkinson Disease and Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit PP1 and PP2A for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress TD-X - Drug Profile Product Description Mechanism Of Action R&D Progress VEL-015 - Drug Profile Product Description Mechanism Of Action R&D Progress Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Products Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Product Development Milestones Featured News & Press Releases Apr 17, 2017: Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model Mar 09, 2017: Late-Breaking Abstract on LB-100, Lixte Biotechnologys Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research Nov 03, 2016: Re-Pharm to present at IDDST, Nanjing, China and available for one-to-one meetings Mar 24, 2016: Re-Pharm compound with steroid-sparing properties granted second patent for ophthalmic indications Feb 03, 2016: Lixte Biotechnology Holdings Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression Nov 24, 2015: Re-Pharm awarded patent for repurposed compound for treatment of inflammatory disorders Nov 06, 2015: Lixte Biotechnology Holdings Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity Sep 17, 2015: Lixte Biotechnology Holdings Engages BioPharmaWorks To Enhance Development Of Its Pipeline Of Novel Compounds Feb 25, 2015: Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies Feb 10, 2015: Re-Pharm identifies novel anti-inflammatory activity for existing compound Jan 23, 2015: Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 Nov 06, 2014: Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch Jun 18, 2014: Lixte's Lead Compound LB-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer Apr 25, 2013: Lixte Biotechnology Initiates Phase I Trial Of Its Lead Anti-Cancer Compound LB-100 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Ampio Pharmaceuticals Inc, H1 2017 Pipeline by Bristol-Myers Squibb Company, H1 2017 Pipeline by Cyano Biotech GmbH, H1 2017 Pipeline by Lixte Biotechnology Holdings Inc, H1 2017 Pipeline by PEP-Therapy SAS, H1 2017 Pipeline by Re-Pharm Ltd, H1 2017 Pipeline by Signum Biosciences Inc, H1 2017 Dormant Projects, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
